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Abstract. Background: The mutational spectrum of mismatch
repair (MMR) genes in the Baltic States has been reported to
be quite similar to that in Poland; however during a country-
wide study considerable differences in the population of Latvia
were discovered. This study was undertaken to investigate the
clinical and molecular features of HNPCC in Latvia. Materials
and Methods: Family cancer histories were collected, from
January 2000 until October 2003, for 702 consecutive hospital
based colorectal cancer (CRC) cases. In families suspected of
having a history consistent with hereditary non-polyposis
colorectal cancer (HNPCC), DNA testing for MLH1, MSH2
and MSH6 genes was performed. Immunohistochemical
examination of the normal and the cancer tissue from large
bowel tumors was undertaken for MSH2 and MSH6 protein
expression in 182 out of 702 (26%) of the cases. Results:
Among the 702 CRC patients only 1 (0.14%) fulfilled the
Amsterdam criteria. Thirteen (1.9%) cases matched the criteria
for suspected HNPCC and 10 (1.4%) cases matched the late
onset HNPCC criteria. Altogether in 7 out of 702 (1%) cases
MMR gene mutations were detected: 2 in MLH1, 3 in MSH2
and 2 in MSH6 gene. Only one out of the seven mutations was
registered in the Human Genome Mutation Database and the
ICG (International Collaborational Group)-HNPCC mutation
data base. Negative MSH2 and MSH6 protein expression was
detected in 4 (2.2%) and 18 out of 182 (9.9%) cases
respectively. Conclusion: The role of the classical Amsterdam
criteria in diagnosing HNPCC in CRC patients from Latvia is
very limited and diagnostic criteria for suspected HNPCC are
the most effective. The frequency of constitutional mutations
within the MMR genes is 1% of all newly diagnosed CRC cases
and the spectrum of mutations is potentially characteristic.
There are approximately 1,000 new colorectal cancer (CRC)
cases diagnosed every year in Latvia and there were 1,119
new cases detected in 2004, which is the highest frequency of
the disease ever registered in Latvia. The CRC cancer
mortality in Latvia was 619 and 673 in 2002 and 2003,
respectively (1).
According to the available epidemiological data, familial
CRC accounts for 10-15% of all colorectal cancers (3), and
one would expect 90-130 familial cases in Latvia per year.
Twenty to 60 of these should be associated with a
hereditary condition [either hereditary non-polyposis
colorectal cancer (HNPCC) or familial adenomatous
polyposis (FAP)]. Important ethnic and geographical
variations of both clinical and molecular features exist in
the case of hereditary CRC in different populations.
Knowledge of the clinical and molecular features is crucial
for successful identification of the risk group of the
hereditary CRC in a particular geographic area. There are
several populations, e.g. from the neighboring Poland and
Finland, where different diagnostic criteria and specific
molecular strategies should be applied (4, 5). According to
an earlier publication the mutational spectrum of
mismatch repair (MMR) genes in the Baltic States showed
a tendency to be quite similar to that in Poland (4).
However the number of cases involved from the Baltic
States was very small, and, therefore, it was necessary to
perform a country-wide study of the clinical and molecular
features of hereditary CRC in Latvia. 
Materials and Methods
A consecutive group of 702 hospital based CRC cases from three
hospitals were selected, from January 2000 to October 2003, for the
study. Cases were considered as consecutive, if at least 70% of
newly diagnosed patients were involved in the study from the
particular hospital and department in the given period of time. In
the study 365 cases were included from the Oncology Center of
Latvia, 173 cases from the Paula Stradins University Hospital and
164 cases from the regional Oncology Hospital of Liepaja. 
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In the study group 365/702 (52%) were females and 337/702
(48%) males. The age group distribution was 7 (1%) cases 30-39
years; 32 (4.56%) cases 40-49 years; 110 (15.67%) cases 50-59 years;
251 (35.75%) cases 60-69 years; 261 (37.18%) cases 70-79 years; 40
(5.7%) cases 80-89 years and 1 (0.14%) case of more than 90 years. 
In order to evaluate the representativity of the study group, it
was compared to all newly diagnosed colorectal cancers diagnosed
between the years 1999 and 2002 in Latvia. According to data from
the Cancer Patients Registry of Latvia (CPRL) during those 4 years
(1999 - 2002) there were 3615 new CRC cases diagnosed in Latvia. 
To compare the two groups the Chi-square (¯2) test was used.
The values p=0.30, (Yates corrected ¯2) for sex distribution;
p<0.68, for age distribution and p<0.97 for distribution of cancer
localization in the large bowel showed that there were no
differences between the groups for these parameters.
The methodology of the study has been accepted by the
Commission of Ethics, Riga Stradins University.
The cancer family history. All patients completed a family cancer
history questionnaire. Family cancer histories were analyzed
according to the diagnostic criteria of hereditary CRC, which are
summarized in Table I. If there were no malignancies among blood
relatives of the proband, the family was classified as negative. If
there was at least one malignancy among blood relatives, but the
family did not match diagnostic criteria of any hereditary CRC
syndrome, then the family was classified as others.
If the pedigree fulfilled the criteria of any hereditary CRC
syndrome, the proband was invited to the Hereditary Cancer
Institute of Riga Stradins University. All of our patients received
counseling with written information about the clinical aspects of
the cancer family syndrome in their family including
recommendations/options concerning prophylactics, surveillance
and treatment. After getting the written informed consent of the
patient, 6 ml of peripheral blood was taken. 
Genetical examinations. In individuals from the families matching
definitive, suspected or extended diagnostic criteria of HNPCC,
DNA testing for the MLH1, MSH2 and MSH6 genes was
performed (8-13). Complete DNA testing for the MLH1 and
MSH2 genes was conducted using the "exon by exon"
DHPLC/sequencing technique (2). If no mutations were found in
the MLH1 and MSH2 genes, in families matching criteria of
definitive or suspected HNPCC, DNA sequencing of four
fragments of the MSH6 gene (ex5 and three fragments of ex4),
where mutations have been most frequently described in the
literature, were performed. In the study group 22/29 (76%)
HNPCC suspected patients, from whom it was possible to obtain
a blood sample, underwent the examinations. 
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Table I. Diagnostic criteria of hereditary colorectal cancer used in the study.
No. Hereditary syndrome or Diagnostic criteria
clinical subgroup
1. Definitive HNPCC (HNPCC) (6-8) Amsterdam I and II criteria.
2. Late onset HNPCC (HNPCC LO) Amsterdam II criteria without age limitation
3. Suspected HNPCC (HNPCC SUSP) (4, 9) Nuclear pedigree criteria of suspected HNPCC: 
1) at least 2 first degree relatives with HNPCC associated cancer 
(colorectal, endometrial, small bowel, ureter, renal pelvis); 
2) at least one cancer should be diagnosed before age 50.
4. Extended HNPCC (HNPCC EXT) (10) 1) At least 2 first degree relatives with HNPCC associated cancer 
(colorectal, ovarian, stomach, hepatobiliary, pancreatic, 
urinary bladder, brain, unknown gynecological); 
2) at least one cancer should be diagnosed before age 50.
5. Familial colorectal cancer (FCC) (3) 1) Colorectal cancer in at least 2 first or second degree relatives; 
2) in at least one colorectal cancer diagnosed before age 60; 
3) HNPCC and FAP should be excluded.
6. Definitive or suspected Hereditary 1) At least 2 breast cancers or 1 breast and 1 ovarian cancer 
breast cancer (HBC) among first degree (or second degree through male) relatives;
2) at least 1 breast cancer in a family diagnosed under age 40.
7. Cancer familial aggregation (CFA) At least 3 first degree blood relatives with malignancy of any localization.
8. Three cancers in blood relatives (3CA) At least 3 blood relatives with malignancy of any localization.
Table II. Clinical frequency of the different subgroups of hereditary
colorectal cancer.
Diagnosis All cases (%)
HNPCC 1 0.14
HNPCC SUSP 13 1.9
HNPCC LO 10 1.4








In individuals from the families matching the criteria of HNPCC
late onset and FCC, DNA sequencing only for the mutations in
four fragments of the MSH6 gene was performed. 8/10 (80%)
HNPCC late onset cases and 5/20 (25%) FCC cases from the study
group were investigated.
Additionally normal and cancer tissue samples from the large
bowel for 182/702 (26%) of the unselected CRC patients
underwent immunohistochemical (IH) examination for the
MSH2 and MSH6 genes protein expression. This is a group of
cases for whom normal and cancer tissue samples were obtained
from the large bowel during surgical resection and the tissue
samples were available in the pathology centers of the hospitals
involved in the study. If homogenous lack of protein expression
in the tumor tissue was detected, complete DNA sequencing for
the gene involved was carried out, if a DNA sample was
available.
All of the molecular analyses were performed in collaboration
with the International Hereditary Cancer Center, Szczecin, Poland.
Results
Clinical features. In 341 (48.6%, CI=45-52.3%) out of the
702 CRC cases no malignancies were recognized among the
relatives. In 361 (51.4%, CI=47.7-55%) of the CRC cases
there was at least one malignancy among blood relatives.
The clinical frequency of the different subgroups of
hereditary CRC are summarized in Table II.
Molecular features. In the study group altogether seven
mismatch repair gene mutations were detected: 2/7 (29%,
CI=8-64%) in MLH1, 3/7 (43%, CI=15-75%) in MSH2 and
2/7 (29%, CI=8-64%) in the MSH6 gene. Overall molecular
frequency of mismatch repair gene mutations is 7/702 (1%,
CI=0.5-2%): 0.72% (CI=0.3-1.7%) for the MLH1/MSH2
gene mutations and 0.28% (CI=0.08-1%) for the MSH6
gene mutation. In 3/7 (43%, CI=16-75%) cases mutations
were of the missense type, in 1/7 (14%, CI=3-51%) case of
the nonsense type and in another 3/7 (43%, CI=16-75%)
cases of the frameshift (deletion) type. Only one out of the
seven mutations was registered in the Human Genome
Mutation Database and ICG (International Collaborational
Group)-HNPCC mutation database.
Molecular features of definitive and suspected HNPCC. In this
group altogether three MMR gene mutations were detected.
In the patient with a mutation in the MSH2 gene ex12, a
missense change of unknown significance in the MLH1 gene
ex17 (1964T/C, I655T) localized in region PMS2 also was
found. No mutations were detected in the one Amsterdam I
positive family.
The mutation detection rate in the suspected HNPCC
group was 3/13 (23%, CI=8-50%). The results of the genetic
examinations of the clinical subgroups of HNPCC can be
seen in Table III.
Molecular features of extended HNPCC. In 1/10 families
matching the extended HNPCC criteria, 1 mutation in the
MLH1 gene ex16 (c.1745 T/C (Leu582Pro) was found. The
MLH1/MSH2 mutation detection rate in the extended
HNPCC group was 1/15 (7%, CI=1.2-29.8%). 
Molecular features of HNPCC late onset. In this group one
mutation in the MSH6 gene ex4 (c.1580delT,frameshift) was
detected. The MSH6 mutation detection rate in the group
was 1/10 (10%, CI=1.8-40.4%). 
Two HNPCC late onset families with considerably earlier
average cancer diagnosis age (52 years in comparison to 60
years and more in the other eight cases) were selected for
MLH1/MSH2 gene sequencing and in one case mutation in
the MSH2 gene ex15 (c.2529-2530 del TG (frameshift)) was
found. Accordingly the MSH2 detection rate in the group
was 1/10 (10%, CI=1.8-40.4%). The overall mutation
detection rate in the HNPCC late onset group was 2/10
(20%, CI=6-51%).
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Table III. Results of the genetic examinations in Amsterdam and suspected HNPCC families.
Diagnosis All Examined %  MLH1, MSH2 MSH6 (4 fragments)
cases cases
Pos Neg Pos Neg
HNPCC 1 1 100% – 1 – 1
HNPCC susp CRC 6 6 100% 2 (MSH2 ex3 (c.508C>T; 4 – 6
Gln170Stop)) (MSH2 ex12; 
c.1786-1788delAAT; 596delAsn)
HNPCC susp Ut 7 5 71% 1 (MLH1 ex12 (G/A 1409+1 4 – 5
caused out of frame del)
Total 14 12 85% 3 9 – 12
Pos-mutation detected; Neg-no mutation; HNPCC susp. CRC-at least 2 colorectal cancers in nuclear pedigree; HNPCC susp. Ut-at least 1
endometrial cancer in nuclear pedigree.
Molecular features of the IH examined group of colorectal
cancers. In 182 cases the MSH2 and MSH6 protein
expression in normal and tumor tissue of the CRC was
evaluated. The frequency of MSH2 protein expression
negative cases in the CRCs was 4/182 (2.2%, CI=0.9-5.5%),
the frequency of MSH6 protein expression negative cases in
the CRCs was 18/182 (9.9%, CI=6.4-15.1%). In 2/182 (1.1%,
CI=0.3-3.9%) tumors both MSH2 and MSH6 negative
protein expression was observed. Altogether in 20/182 (11%,
CI=7.2-16.4%) patients negative protein expression of either
or both of the MSH2 or MSH6 genes was observed. 
In 15/20 (75%) patients with negative protein expression
it was possible to obtain blood samples. No mutations 0/3
(0%, CI=0-56%) were detected in complete MSH2 gene
sequencing of the negative MSH2 gene protein expression
cases. In 1/14 (7.1%, CI=1-31%) cases of negative MSH6
gene protein expression, a missense mutation in the MSH6
gene (ex4 Phe985Leu(C/G)) was found. In this case negative
expression of the MSH2 gene protein was also detected. In
1/2 (50%, CI=9-91%) cases with negative protein
expression of both the MSH2 and MSH6 genes, a mutation
in the MSH6 gene was found. 
Discussion
The results of this study have shown that the frequency of
Amsterdam positive families in Latvia is 0.14% of all newly
diagnosed CRC cases. The closest frequency of Amsterdam
positive families has been reported from the United
Kingdom, where 0.3% of all newly diagnosed CRC cases
matched those diagnostic criteria (11). In other studies from
Sweden, Denmark, Finland, Italy, USA and Israel, the
incidence of Amsterdam positive cases is between 0.5% and
1.5% of all newly diagnosed CRC cases (12-17). Raedle et
al. have reported a 3.2% frequency of Amsterdam positive
cases in their series in Germany; however, the number of
CRC patients involved in that study was only 145 (18).
According to the available data it is possible to conclude
that the Amsterdam positive families frequency of 0.14% in
our study is smaller than in all other previously studied
Western populations. However, this difference is statistically
significant only in comparison with the frequencies reported
from Denmark and Germany (13, 18), and not to all the
other cases reported in our discussion. Unfortunately, it is
not possible to exclude bias related to the poor reliability of
collected pedigree information. Many families have small
numbers of relatives and they have very poor medical
information about one another for several different
historical reasons. Also another study from Eastern Europe
has reported on the limitations of the application of
pedigree/clinical data in the diagnosis of HNPCC due to
poor availability of medical documentation of patients’
relatives and the small size of contemporary families (20). 
Molecular results from this study revealed that all seven
families with MMR gene mutations did not fulfill the
Amsterdam criteria. In addition, a case published earlier by
our group with a mutation in the MSH6 gene ex4 also did
not fulfill the Amsterdam criteria (19). This confirms the
other reports that in certain populations the use of the
Amsterdam criteria is very limited and alone they are not
sufficient to identify the majority of families with MMR
gene mutations (20). Such a conclusion is further confirmed
by finding that in the majority of the mutation positive
families only two or fewer cancers were revealed in the
pedigree. This is in contrast with a report of Park, where
only a small proportion of the patients had MLH1/MSH2
mutations in families not matching the Amsterdam criteria
(8). Thus, the use of particular HNPCC diagnostic criteria
should be adapted for different geographical regions. 
Additionally, it should be mentioned that the first
reported HNPCC family in Latvia with a mutation in the
MSH2 gene fulfilled the classical Amsterdam I criteria (21).
But since 1997 it remains the only case of a "good"
Amsterdam family in Latvia.
There are only a few reports on the incidence of
suspected HNPCC criteria in other populations and
nuclear pedigree criteria for suspected HNPCC were not
always used. The 1.7% frequency of suspected HNPCC
cases reported from Finland is very similar to the 1.9% in
our study (14). The incidence reported from the United
Kingdom is slightly lower at 1.4% (11). A considerably
higher proportion, using nuclear pedigree criteria has been
reported from Poland with 6.84% (CI=5.1-9.1%) of all
newly diagnosed CRCs (20), as well from Italy with 4.6%
(CI=3.7-5.7%) (22); this difference is statistically
significant (20, 22).
The mutation detection rate in the suspected HNPCC
group was 23% in the present study which is comparable to
other reports, where the rate was between 29% and 34% (8,
20, 23). Such a relatively high mutation detection rate
confirms the efficacy of the suspected HNPCC criteria
identifying the families with MMR gene mutations and
diagnosing HNPCC. Fifty percent (3/6) of the mutations in
our study were detected in the suspected HNPCC group.
Although the suspected HNPCC criteria are less specific
than the Amsterdam criteria for the detection of families
with MMR gene mutations (25-34% vs. 50-60%), our results
in agreement with several other reports have clearly shown
that the use of the suspected HNPCC criteria allows the
identification of the majority of HNPCC cases. 1.4% of the
cases in our study fulfilled the HNPCC late onset criteria.
There are no reports of the frequency of those criteria in
other populations. The frequency of MSH6 gene ex4
mutations in the group was 10% (1/10) in our study.
Another MSH6 gene ex4 mutation published earlier by
our group was also detected in a family matching the
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HNPCC late onset criteria (19). This finding is in
agreement with other reports on the later onset of cancer
with the MSH6 phenotype compared to MLH1/MSH2
cancers (24-27). More than 40 MSH6 mutations have been
reported in the literature and the average age of onset for
colorectal and endometrial cancer was 53 and 56 years,
respectively (24). The average colorectal and endometrial
cancer onset age in the two MSH6 families in our study
was 62.5 (5 cases) and 57.5 (2 cases), respectively. The
average CRC onset age is considerably later, but the
number of cases is not sufficient to draw any conclusions
on the MSH6 phenotype. However, the importance of
recognizing the HNPCC late onset group in order to
diagnose this subgroup of HNPCC and to select patients
for MSH6 gene ex4 testing has been confirmed by this
study and other reports. 
The molecular frequency of HNPCC was 1% in our
study, which was very similar to the 0.86% reported from
the USA (28) and 0.8% in Denmark, (13) while a lower
incidence of 0.3% has been reported in Italy (29). Foulkes et
al. reported 0.44% molecular frequency of HNPCC in
Israel, but only the most frequent found mutation was
tested in that study (17). A considerably higher incidence of
2.0-2.7% has been reported in Finland (30), 2.7% in
Germany (31) and Poland (20, 30, 31).
Seven out of the nine (78%) mutations detected in Latvia
so far have not been reported previously in either the
Human Genome Mutation Database or in the ICG-HNPCC
mutation database. According to our results, the MMR
mutation spectrum in HNPCC patients in Latvia is different
from the neighboring countries, such as Poland, Finland,
Estonia and Lithuania. No significant effect in HNPCC
cases has been detected in Latvia so far, and the mutation
spectrum has to be considered as potentially unique. 
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